Review
Oncology
Jie Deng, Rongqi Jiang, Enqing Meng, Hao Wu
Summary: CXCL5, a chemokine, plays a critical role in human malignant tumors, potentially associated with tumor metastasis and angiogenesis. Regulating CXCL5 may be a promising approach for tumor therapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Teresa Gonzalez Munoz, Ana Teresa Amaral, Pilar Puerto-Camacho, Hector Peinado, Enrique de Alava
Summary: Endoglin has been identified as a potential disease biomarker and therapeutic target, playing various roles in physiological and pathological processes. It acts as a co-receptor in the TGF beta pathway and can also be released in soluble form to affect cell signaling. In cancer, endoglin may contribute to both oncogenic and non-oncogenic phenotypes, opening up possibilities for targeted therapies within the tumor microenvironment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Jie Deng, Xuejiao Ma, Yang Ni, Xiaomin Li, Wenjing Xi, Minqi Tian, Xing Zhang, Manyu Xiang, Wanglong Deng, Chao Song, Hao Wu
Summary: This study evaluated the immune microenvironment of NSCLC patients treated with PD-1 inhibitors and found that CXCL5 may serve as a potential biomarker for prognosis and responsiveness to immunotherapy, suggesting it as a novel preventive and therapeutic target for NSCLC.
Review
Oncology
Sabrina Rizzolio, Silvia Giordano, Simona Corso
Summary: In the last two decades, targeted drugs have revolutionized clinical oncology. However, primary and acquired resistance to these therapies has become a significant limitation, with cancer-associated fibroblasts (CAFs) playing a crucial role. CAFs not only contribute to tumor stroma structure, but also release various molecules that impact tumor properties, including response to drug treatment. The role of CAFs in resistance to targeted therapies, particularly molecular therapies, has been overlooked.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Yuanyuan An, Qing Yang
Summary: Ovarian cancer is influenced significantly by the tumor microenvironment, where macrophages play a crucial role in regulating the progression of the disease. Targeted therapy focusing on macrophages shows promise in treating ovarian cancer, despite facing challenges. Interactions between macrophages and other immune cells within the microenvironment also impact the development of ovarian cancer.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Chemistry, Multidisciplinary
Changlong Wang, Xiaojun Wang, Wei Zhang, Ding Ma, Feng Li, Rongrong Jia, Min Shi, Yugang Wang, Guanghui Ma, Wei Wei
Summary: The study demonstrates that shielding Fn with a CaP shell can enhance delivery performance by reducing interception in the liver and re-exposing it in acidic tumors, potentially leading to therapeutic effects.
ADVANCED MATERIALS
(2022)
Article
Immunology
Pauline Delobel, Benjamin Ginter, Eliane Rubio, Karl Balabanian, Gwendal Lazennec
Summary: The chemokine receptor Cxcr2 plays a crucial role in neutrophil physiology, as evidenced by the findings from Cxcr2 knockout mice. Cxcr2 deficiency leads to decreased percentage of mature neutrophils in the spleen and increased accumulation of aged neutrophils. It also affects their phagocytic ability and signaling pathways.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Hsin-Lun Lee, Yi-Chieh Tsai, Narpati Wesa Pikatan, Chi-Tai Yeh, Vijesh Kumar Yadav, Ming-Yao Chen, Jo-Ting Tsai
Summary: Hepatocellular carcinoma is a common malignancy with high mortality rate. Radiotherapy is an effective non-surgical treatment option, but its efficacy is limited in advanced and recurrent tumors. Tumor-associated macrophages (TAMs) play a crucial role in radiotherapy response. In this study, we identified the potential of targeting the TAM/CXCL6/CXCR2 tumor immune signaling axis as a new treatment strategy for radiotherapy-resistant hepatocellular carcinoma cells.
Review
Immunology
Xiaohan Guo, Yi Wu, Ying Xue, Na Xie, Guobo Shen
Summary: Recent progress in immunotherapy has revolutionized cancer treatment by utilizing bispecific antibodies (BsAbs) to activate the patient's immune system for targeted elimination of cancer cells. BsAbs can identify various cancer targets and exert effector activities by redirecting cellular pathways. However, further research is needed to optimize conditions, identify appropriate combination partners, and reduce toxicity.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Pharmacology & Pharmacy
Yanyan Xu, Jingyuan Xiong, Xiyang Sun, Huile Gao
Summary: Cancer immunotherapy has flourished and revolutionized tumor therapies, but challenges such as low patient response rates and immune-related side effects remain. The immunosuppressive tumor microenvironment (TME) plays a pivotal role in tumor progression and metastasis, but also provides targets for remodeling the TME. Remodeling the TME and strengthening patients' immune systems can improve the effectiveness of immunotherapy.
ACTA PHARMACEUTICA SINICA B
(2022)
Review
Biochemistry & Molecular Biology
Haiying Que, Qianmei Fu, Tianxia Lan, Xiaohe Tian, Xiawei Wei
Summary: This review discusses the complex roles of neutrophils in the tumor microenvironment and highlights the progress in neutrophil-targeted therapies in ongoing clinical trials.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2022)
Review
Oncology
Gaoqi Chen, Kaiwen Wu, Hao Li, Demeng Xia, Tianlin He
Summary: Hypoxia, a key element in the tumor microenvironment, plays a crucial role in tumor cell behavior and has potential therapeutic targets. This review discusses the effects of hypoxia on tumor behavior and its interaction with the tumor microenvironment from various perspectives, including immune cells, cell metabolism, oxidative stress, and HIF. The current therapies targeting hypoxia, such as glycolysis inhibitors, anti-angiogenesis drugs, HIF inhibitors, hypoxia-activated prodrugs, and hyperbaric medicine, are also summarized.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Dan Wang, Yingying Han, Lushan Peng, Tao Huang, Xiaoyun He, Junpu Wang, Chunlin Ou
Summary: N6-methyladenosine (m6A) is the most abundant RNA modification in eukaryotes, which regulates the expression and function of both coding and non-coding RNAs (ncRNAs) in various diseases, including malignant tumors. Recent studies have shown that the crosstalk between m6A modifications and ncRNAs plays an important role in the biological regulation of the tumor microenvironment (TME). This review provides a deeper understanding of the relationship between m6A-related ncRNAs and TME, which is of great significance for the development of precise tumor therapy strategies.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2023)
Article
Oncology
Faya Zhang, Oscar Mulvaney, Erica Salcedo, Subrata Manna, James Z. Zhu, Tao Wang, Chul Ahn, Laurentiu M. Pop, Raquibul Hannan
Summary: This study found that radiation therapy induces early innate inflammatory response in the tumor microenvironment through the activation of the CXCLs/CXCR2 axis. Neutrophils infiltrate the tumor through CXCR2, and blocking CXCR2 can reduce neutrophil infiltration. Additionally, radiation also activates the CXCLs/CXCR2 axis via DNA sensing pathways, leading to inflammation in the tumor microenvironment.
Review
Oncology
Carmelo Laface, Girolamo Ranieri, Felicia Maria Maselli, Francesca Ambrogio, Caterina Foti, Michele Ammendola, Marigia Laterza, Gerardo Cazzato, Riccardo Memeo, Giovanni Mastrandrea, Marco Lioce, Palma Fedele
Summary: One of the most important abilities of a tumor is to establish immunosuppression inside the tumor microenvironment. This is achieved through various mechanisms of tumor immune escape identified in experimental studies. In the liver, the microenvironment is oriented towards immune tolerance, preventing autoimmune reactions. Additionally, hepatocellular carcinoma often develops in the context of chronic inflammation. Due to these factors, different immunotherapeutic strategies have been developed and evaluated for advanced HCC. This review provides an overview of the clinical applications of immunotherapy for advanced HCC, including approved drugs and ongoing clinical trials.
